Skip to main content

Karbe Frank

No open-market purchases or sales filed in the past year.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
–
0 filings
Net
–
Bought minus sold
Companies
0
With open-market trades

Trades

Every Form 4 that lists Karbe Frank as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

PHAT Phathom Pharmaceuticals, Inc.

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 16, 2024 (view filing)Dec 133 daysKarbe FrankDirectorPPurchase+12.5K$7.93+$99.1K+28.1%57.0K after

BTTX Better Therapeutics, Inc.

Chief Executive Officer3 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 31, 2023 (view filing)Jul 274 daysKarbe FrankChief Executive OfficerPPurchase+137.0K$0.73+$100.0K+46.9%429.4K after
Apr 12, 2023 (view filing)Apr 102 daysKarbe FrankSee RemarksPPurchase+242.4K$0.83+$201.2K+484.8%292.4K after
Sep 15, 2022 (view filing)Sep 15Same dayKarbe FrankSee RemarksPPurchase+50.0K$2.09+$104.5KNew position50.0K after

MYOV Myovant Sciences Ltd.

Principal Fin'l & Accounting1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 9, 2021 (view filing)Jul 72 daysKarbe FrankPrincipal Fin'l & AccountingSSale−3.23K$21.75−$70.3K−1.5%212.3K after